Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart

• Published in: Circulation (New York, N.Y.) N.Y.), 2004-03, Vol.109 (8), p.1029-1035
• Main Authors: RUTANEN, Juha, RISSANEN, Tuomas T, STACKER, Steven A, ACHEN, Marc G, HARTIKAINEN, Juha, YLÄ-HERTTUALA, Seppo, MARKKANEN, Johanna E, GRUCHALA, Marcin, SILVENNOINEN, Päivi, KIVELÄ, Antti, HEDMAN, Antti, HEDMAN, Marja, HEIKURA, Tommi, ORDEN, Maija-Riitta
• Format: Article
• Language: English
• Subjects: Adenoviridae - genetics; Angiogenesis Inducing Agents - administration & dosage; Angiogenesis Inducing Agents - therapeutic use; Animals; Biological and medical sciences; Blood and lymphatic vessels; Cardiac Catheterization; Cardiac Tamponade - etiology; Cardiology. Vascular system; Coronary Circulation; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous; Echocardiography, Doppler; Genetic Therapy - adverse effects; Genetic Vectors - administration & dosage; Injections; Medical sciences; Myocarditis - etiology; Myocardium; Pericardial Effusion - etiology; Swine; Vascular Endothelial Growth Factor A - genetics; Vascular Endothelial Growth Factor A - physiology; Vascular Endothelial Growth Factor D - genetics; Vascular Endothelial Growth Factor D - physiology
• ISSN: 0009-7322; 1524-4539
• DOI: 10.1161/01.cir.0000115519.03688.a2

It is unclear what is the most efficient vector and growth factor for induction of therapeutic vascular growth in the heart. Furthermore, the histological nature of angiogenesis and potential side effects caused by different vascular endothelial growth factors (VEGFs) in myocardium have not been documented. Adenoviruses (Ad) at 2 doses (2x10(11) and 2x10(12) viral particles) or naked plasmids (1 mg) encoding LacZ control, VEGF-A165, or the mature, soluble form of VEGF-D (VEGF-D(DeltaNDeltaC)) were injected intramyocardially with the NOGA catheter system into domestic pigs. AdVEGF-D(DeltaNDeltaC) gene transfer (GT) induced a dose-dependent myocardial protein production, as measured by ELISA, resulting in an efficient angiogenic effect 6 days after the injections. Also, AdVEGF-A165 produced high gene transfer efficacy, as demonstrated with immunohistochemistry, leading to prominent angiogenesis effects. Despite the catheter-mediated approach, angiogenesis induced by both AdVEGFs was transmural, with maximal effects in the epicardium. Histologically, strongly enlarged alpha-smooth muscle actin-positive microvessels involving abundant cell proliferation were found in the transduced regions, whereas microvessel density did not change. Myocardial contrast echocardiography and microspheres showed marked increases in perfusion in the transduced areas. VEGF-D(DeltaNDeltaC) but not matrix-bound VEGF-A165 was detected in plasma after adenoviral GT. A modified Miles assay demonstrated myocardial edema resulting in pericardial effusion with the higher AdVEGF doses. All effects returned to baseline by 3 weeks. Naked plasmid-mediated GT did not induce detectable protein production or vascular effects. Like AdVEGF-A165, AdVEGF-D(DeltaNDeltaC) GT using the NOGA system produces efficient transmural angiogenesis and increases myocardial perfusion. AdVEGF-D(DeltaNDeltaC) could be useful for the induction of therapeutic vascular growth in the heart.